FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 09/316,199	ATTY. DOCKET NO.: C1040.70006US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: May 21, 1999	CONFIRMATION NO.: 7506
	APPLICANT: McCluskie et al.	
Sheet 1 of 3	GROUP ART UNIT: 1632	EXAMINER: Dave Nguyen

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
DV	A1	6,174,872		Carson et al.	01/16/2001
	A2	6,194,388		Krieg et al.	02/27/2001
	A3	6,207,646		Krieg et al.	03/27/2001
	A4	6,214,806		Krieg et al.	04/10/2001
	A5	6,218,371		Krieg et al.	04/17/2001
	A6	6,239,116		Krieg et al.	05/29/2001
	A7	6,339,068		Krieg et al.	01/15/2002
	A8	6,406,705		Davis et al.	06/18/2002
	A9	6,429,199		Krieg et al	08/06/2002
	A10	6,514,948		Raz et al.	02/04/2003
	A11	6,562,798		Schwartz	05/13/2003
	A12	6,589,940		Raz et al.	07/08/2003
	A13	6,610,661		Carson et al.	08/26/2003
V	A14	6,613,751		Raz et al.	09/02/2003

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document Office/ Country	Number	Kind Code	Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
DV	/	US	20020055477A1		Nest et al.	05/09/2002	
	/	US	20020142978A1		Raz et al.	10/03/2002	
	/	US	20020156003A1		Bratzler et al.	10/24/2002	
	/	US	20030026782A1		Krieg et al.	02/06/2003	
	/	US	20030049266A1		Fearson et al.	03/13/2003	
		US	20030050263A1		Krieg et al.	03/15/2003	
	/	US	20030078223A1		Raz et al.	04/24/2003	
	/	US	20030092663A1		Raz	05/15/2003	
	/	US	20030109469A1		Carson et al.	06/12/2003	
	/	US	20030119773A1		Raz et al.	06/26/2003	
	/	US	20030147870A1		Raz et al.	08/07/2003	
	/	US	20030186921A1		Carson et al.	10/02/2003	
		WO	98/16247		The Regents of The University of California	04/23/1998	
		WO	99/11275		The Regents of The University of California	03/11/1999	
		WO	99/62923		Dynavax	12/09/1999	
		WO	00/20039		The Regents of The University of California	04/13/2000	
		WO	00/21556 A1		Dynavax	04/20/2000	
V		WO	01/02007 A1		The Regents of The University of California	01/11/2001	
		WO	01/12223 A2		Dynavax	02/22/2001	

DM 2/11/04

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 09/316,199	DOCKET NO.: C1040.70006US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: May 21, 1999	CONFIRMATION NO.: 7506
	APPLICANT: McCluskie et al.	
Sheet 2 of 3	GROUP ART UNIT: 1632	EXAMINER: Dave Nguyen

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
DA	C1	Choi AH et al., "The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependant on the route and the coadministered adjuvant", *Vaccine.* 2002 Mar 15;20(13-14): 1733-40.		
	C2	Davis, HL, "Use of CpG DNA for enhancing specific immune responses", *Curr Top Microbiol Immunol.* 2000; 247: 171-83.		
	C3	Dumais, N. et al., "Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleoties induce genital immune responses and protection against intravaginal challenge", J. Infect. Dis. 2002 Oct 15; 186(8):1098-105. Epub 2002 Sept.		
	C4	Gallichan, W. Scott et al., "Intranasal Immunization with CpG Oligodeoxynucleotides as an Adjuvant Dramatically Increases IgA and Protection Against Herpes Simplex Virus-2 in the Genital Tract", *The Journal of Immunology,* 2001, 166: 3451-3457.		
	C5	Hartmann, G et al., "Delineation of a CpG Phosphorothiaote Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo", *The Journal of Immunology,* 2000, 164: 1617-1624.		
	C6	Kovarik, J et al., "CpG Oligodeoxynucleotides Can Circumvent the Th2 Polarization of Neonatal Responses to Vaccines But May Fail to Fully Redirect Th2 Responses Established by Neonatal Priming", *The Journal of Immunology,* 1999, 162: 1611-1617.		
	C7	Kovarik, J et al., "Adjuvant effect of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens", *Immunology.* 2001 Jan; 102(1): 67-76..		
	C8	Krieg, AM et al., "Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal L. monocytogenes challenge", Abstract from 1996 meeting on *Molecular Approaches to the Control of Infectious Diseases,* Cold Spring Harbor Laboratory, September 9-13, 1996. p.116.		
	C9	Krieg, AM, "CpG oligoneucleotides as immune adjuvants", *Ernst Schering Res. Found Workshop,* 2000; (30): 105-18.		
	C10	Krieg, AM, "Immune Effects and mechanisms of action of CpG motifs", *Vaccine.* 2001 Nov. 8; 19(6): 618-22.		
	C11	Krieg, AM et al., "Enhancing vaccines with immune stimulatory CpG DNA", *Curr Opin Mol Ther.* 2001 Feb; 3(1):15-24		
	C12	Liu, Hsin-Ming et al., "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Responses to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor", *Blood,* Vol 92, No. 10 (November 15), 1998: pp 3730-3736		
	C13	Malanchere-Bres, E et al., "CpG Oligodeoxynucleotides with Hepatitis B Surface Antigen (HBsAg) for Vaccination in HBsAg-Transgenic Mice", *Journal of Virology,* July 2001, p. 6482-6491		
	C14	Brazolot Millan, Cynthia L. et al., "CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice", *Proc. Natl. Acad. Sci. USA,* Vol. 95, pp. 15553-15558, December 1998 Immunology		
	C15	McCluskie, MJ et al., "Muscol immunization with DNA vaccines", *Microbes Infect.* 1999 Jul; 1(9): 685-98.		
	C16	McCluskie, MJ et al., "CpG DNA as mucosal adjuvant", *Vaccine.* 1999 Sep; 18(3-4): 231-7.		
	C17	McCluskie, MJ et al., "The role of CpG in DNA vaccines", *Springer Semin Immunopathol.* 2000; 22(1-2): 125-32.		
	C18	McCluskie, MJ et al., "CpG DNA is an effective oral adjuvant to protein antigens in mice", *Vaccine.* 2000 Nov 22; 19(7-8): 950-7.		
	C19	McCluskie, MJ et al., "Intranasal immunization of mice with CpG DNA induces strong systematic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution", *Mol Med.* 2000 Oct; 6(10): 867-77.		

DA 2/9/04

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 09/316,199	DOCKET NO.: C1040.70006US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: May 21, 1999	CONFIRMATION NO.: 7506
	APPLICANT: McCluskie et al.	
Sheet 3 of 3	GROUP ART UNIT: 1632	EXAMINER: Dave Nguyen

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
DN	C20	McCluskie, MJ et al., "Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants", *Vaccine* 19 (2001) 413-422		
	C21	McCluskie, MJ et al., "The potential of CpG oligodeoxynucleotides as muscol adjuvants", *Crit Rev Immunol.* 2001; 21(1-3): 103-20		
	C22	McCluskie, MJ et al., "The use of CpG DNA as mucosal vaccine adjuvant", *Curr Opin Investig Drugs.* 2001 Jan; 2(1): 35-9.		
	C23	McCluskie, MJ et al., "The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants", *Vaccine.* 2001 Mar 21; 19(17-19): 2657-60.		
	C24	McCluskie, MJ et al., "Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants", *Vaccine.* 2001 Jun 14; 19(27): 3759-68.		
	C25	McCluskie, MJ et al., "Parenteral and mucosall prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA", *FEMS Immunol Med Microbiol.* 2002 Feb 18; 32(3): 179-85.		
	C26	Pal, S. et al., "Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlaymdial challenge", *Infect Immun.* 2002 Sep; 70(9): 4812-7.		
	C27	Payette PJ et al., "History of vaccines and positioning of current trends", *Curr Drug Targets Infect Disord.* 2001 Nov; 1(3): 241-7.		
	C28	Sajic D et al., "Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge", *J Med Virol.* 2003 Dec; 71(4):561-568.		
	C29	Weeratna, RD et al., "CpG ODN allows lower doses of antigen against hepatitis B surface antigen in BALB/c mice", *Immunol Cell Biol.* 2003 Feb; 81(1): 59-62.		
	C30	Weeratna, RD et al., "CpG ODN can redirect the Th bias of established Th2 immune responses in adult and young mice", *FEMS Immunol Med Microbiol.* 2001 Dec; 32(1): 65-71.		
	C31	Weeratna, RD., "Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies", *FEMS Immunol Med Microbiol.* 2001 Apr; 30(3): 241-7.		
	C32	Weeratna, RD, "CpG DNA induces stronger immune responses with less toxicity than other adjuvants", *Vaccine.* 2000 Mar 6; 18(17): 1755-62.		

EXAMINER	DATE CONSIDERED
DN	2/9/04

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. C1040/7006	SERIAL NO. 09/316,199
	APPLICANT McCluskie et al.	
	FILING DATE May 21, 1999	GROUP

U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate
	A1	3,906,092	09/16/75	Hilleman et al.			
	A2	5,248,670	09/28/93	Draper et al.	514	44	
	A3	5,585,479	12/17/96	Hoke et al.	536	24.5	
	A4	5,663,153	09/02/97	Hutcherson et al.	514	44	
	A5	5,786,189	07/28/98	Locht et al.	435	172.3	
	A6	5,849,719	12/15/98	Carson et al.	514	44	
	A7	5,723,335	03/03/98	Hutcherson, et al.	435	375	

FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes	Translation No
	B1	WO 91/12811	09/05/91	PCT	A61K	31/70		
	B2	0468520	01/29/92	EPO	A61K	31/70		
	B3	WO 92/03456	03/05/92	PCT	C07H	15/12		
	B4	WO 92/18522	10/29/92	PCT	C07H	21/00		
	B5	WO 92/21353	12/10/92	PCT	A61K	31/70		
	B6	0302758 B1	03/16/94	EPO	C12N	15/37		
	B7	WO 94/19945	09/15/94	PCT	A01N	43/04		
	B8	WO 95/05853	03/02/95	Regents of the University of CA				
	B9	WO 95/26204	10/95	PCT	A61K	48/00		
	B10	WO 96/02555	02/01/96	PCT				
	B11	WO 96/35782	11/14/96	Applied Research Systems				
	B12	WO 97/28259	08/07/97	PCT	C12N	15/00		
	B13	WO 98/18810	05/07/98	PCT	C07H	21/00		
	B14	WO 98/37919	09/03/98	PCT	A61K	49/00		
	B15	WO 98/40100	09/17/98	PCT	A61K	39/39		
	B16	WO 98/52581	11/26/98	PCT	A61K	35/00		
	B17	WO 98/14210	04/09/98	PCT	A61K	39/35		

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

	C1	Adya N et al., Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB. *Proc Natl Acad Sci USA* 91(12):5642-6, 7 Jun 1994.
	C2	Angier, N., Microbe DNA Seen as Alien By Immune System, *New York Times*, 4/11/95

2/9/04

FORM PTO-1449 (Modified)	ATTY. DOCKET NO.	SERIAL NO.
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	C1040/7006	09/316,199
	APPLICANT McCluskie et al.	
	FILING DATE May 21, 1999	GROUP

DV	C3	Azad RF et al., Antiviral Activity of a Phosphorothioate Oligonucleotide Complementary to RNA of the Human Cytomegalovirus Major Immediate-Early Region. *Antimicrobial Agents and Chemotherapy*, 37:1945-1954, September, 1993.
	C4	Azuma, Biochemical and Immunological Studies on Cellular Components of Tubercle Bacilli, *Kekkaku*, Vol. 69, 9:45-55, 1992.
	C5	Ballas ZK et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. *J Immunol* 157(5):1840-5, 1996.
	C6	Bayever, E., Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial, *Antisense Res. & Dev.* (1993), 3:383-390.
	C7	Bennett RM et al., DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA. *J Clin Invest* 76(6):2182-90, 1985.
	C8	Berg DJ et al., Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. *J Clin Invest* 96(5):2339-47, 1995.
	C9	Blanchard DK et al., Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages. *J Immunol* 136(3):963-70, 1986.
	C10	Blaxter et al., Genes expressed in Brugia malayi infective third stage larvae. *Molecular and Biochemical Parasitology*, 77:77-93.
	C11	Boggs RT et al., Characterization and modulation of immune stimulation by modified oligonucleotides. *Antisense Nucleic Acid Drug Dev* 7(5):461-71, Oct 1997.
	C12	Branda RF et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides. *J. Lab Clin Med* 128(3):329-38, Sep 1996.
	C13	Branda et al., Immune Stimulation by an Antisense Oligomer Complementary to the rev gene of HIV-1. *Biochemical Pharmacology*, Vol. 45, 10:2037-2043, 1993.
	C15	Chace, J. et al., Regulation of Differentiation in CD5+ and Conventional B Cells, *Clinical Immunology and Immunopathology*, (1993), 68:3:327-332.
	C16	Chang YN et al., The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements. *J Virol* 64(1):264-77, Jan 1990.
	C17	Chu RS et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. *J Exp Med* 186(10):1623-31, 17 Nov 1997.
	C18	Chow Y et al., Improvement of Hepatitis B Virus DNA Vaccines by Plasmids Coexpressing Hepatitis B Surface Antigen and Interleukin-2, *Journal of Virology*, Vol. 71, No. 1, pp. 169-178, Jan. 1997.
	C19	Chow Y et al., Development of Th1 and Th2 Populations and the Nature of Immune Responses to Hepatitis B Virus DNA Vaccines Can Be Modulated by Codelivery of Various Cytokine Genes, *The Journal of Immunology*, 160:1320-1329, 1998.
	C20	Corr M et al., Gene Vaccination with Naked Plasmid DNA: Mechanism of CTL Priming, *J. Exp. Med.*, Vol. 184, 155-1560, October 1996.
	C21	Cowdery JS et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. *J Immunol* 156(12):4570-5, 15 Jun 1996.
	C22	Crosby et al., The Early Responses Gene FGFI-C Encodes a Zinc Finger Transcriptional Activator and is a Member of the GCGGGGGCG (GSG) Element-Binding Protein Family. *Mol. Cell. Biol.*, 2:3835-3841, 1991.
V	C23	Crystal, Transfer of Genes to Humans: Early Lessons and Obstacles to Success. *Science*, Vol. 270, pp. 404-410, 1995.
	C24	D'Andrea A et al., Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. *J Exp Med* 178(3):1041-8, 1993.

DVH 2/9/04

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. C1040/7006	SERIAL NO. 09/316,199
	APPLICANT McCluskie et al.	
	FILING DATE May 21, 1999	GROUP

	C25	Daheshia M et al., Immune induction and modulation by topical ocular administration of plasmid DNA encoding Antigens and cytokines, *Vaccine*, Vol. 16, No. 11/12, pp. 1103-1110, 1998.
	C26	Daynes RA et al., Induction of Common Mucosal Immunity by Hormonally Immunomodulated Peripheral Immunization, *Infection and Immunity*, Vol. 64, No. 4, pp. 1100-1109, Apr. 1996.
	C27	Englisch et al., Chemically Modified Oligonucleotides as Probes and Inhibitors, *Angew. Chem. Int. Ed. Engl.* 30:613-629, 1991.
	C28	Erb KJ et al., Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. *J Exp Med* 187(4):561-9, 16 Feb 1998.
	C29	Etlinjer, Carrier sequence selection - one key to successful vaccines, *Immunology Today*, Vol. 13, 2:52-55, 1992.
	C30	Fox RI, Mechanism of action of hydroxychloroquine as an antirheumatic drug. *Chemical Abstracts*, 120:15, Abstract No. 182630 (April 29, 1994).
	C31	Gordon et al., Safety, Immunogenicity, and Efficacy of a Recombinantly Produced *Plasmodium falciparum* Circumsporozoite Protein-Hepatitis B Surface Antigen Subunit Vaccine, *JID*, 171, pp. 1576-1585, June 1995.
	C32	Gura, T., Antisense Has Growing Pains. *Science* (1995), 270:575-576.
	C33	Hadden J et al., Immunostimulants. *TIPS*, (1993), 141:169-174.
	C34	Hadden J et al., Immunopharmacology, *JAMA*, (1992) 268:20:2964-2969.
	C35	Halpern MD et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. *Cell Immunol* 167(1):72-8, 1996.
	C36	Hatzfeld J., Release of Early Human Hematopoietic Progenitors from Quiescence by Antisense Transforming Growth Factor β1 or Rb Oligonucleotides, *J. Exp. Med.*, (1991) 174:925-929.
	C37	Heppner et al., Safety, Immunogenicity, and Efficacy of *Plasmodium falciparum* Repeatless Circumsporozoite Protein Vaccine Encapsulated in Liposomes, *JID*, 174, pp. 361-366, August 1996.
	C38	Highfield PE, Sepsis: the More, the Murkier. *Biotechnology*, 12:828, August 12, 1994.
	C39	Hoeffler JP et al., Identification of multiple nuclear factors that interact with cyclic adenosine 3',5'-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions. *Mol Endocrinol* 5(2):256-66, Feb 1991.
	C40	Horspool JH et al., Nucleic Acid Vaccine-Induced Immune Responses Require CD28 Costimulation and Are Regulated by CTLA4, *The Journal of Immunology*, 160:2706-2714, 1998.
	C41	Iguchi-Ariga SM and Shaffner W, CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. *Genes Dev* 3(5):612-9, May 1989.
	C42	Iverson, P., et al., "Pharmacokinetics of an Antisense Phosphorothioate Oligodeoxynucleotide against reve from Human Immunodeficiency Virus Type 1 in the Adult male Rate Following Single Injections and Continuous Infusion", *Antisense Research and Development*, (1994), 4:43-52
	C43	Ishikawa R et al., IFN induction and associated changes in splenic leukocyte distribution. *J Immunol* 150(9):3713-27, 1 May 1993
	C46	Kim JJ et al., In Vivo Engineering of a Cellular Immune Response by Coadministration of IL-12 Expression Vector With a DNA Immunogen, *The Journal of Immunology*, 158:816-826, 1997.
	C47	Kimura Y et al., Binding of Oligoguanylate to Scavenger Receptors Is Required for Oligonucleotides to Augment NK Cell Activity and Induce IFN, *J. Biochem.*, Vol. 116, 5:991-994, 1994.
	C48	Kline JN et al., CpG motif oligonucleotides are effective in prevention of eosinophilic inflammation in a murine model of asthma. *J Invest Med* 44(7):380A, 1996.
	C49	Kline JN et al., Immune redirection by CpG oligonucleotides. Conversion of a Th2 response to a Th1 response in a murine model of asthma. *J Invest Med* 45(3):282A, 1997.

Dale 2/9/04

FORM PTO-1449 (Modified)	ATTY. DOCKET NO.	SERIAL NO.
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	C1040/7006	09/316,199
	APPLICANT McCluskie et al.	
	FILING DATE May 21, 1999	GROUP

	C50	Kline JN et al., CpG oligonucleotides can reverse as well as prevent Th2-mediated inflammation in a murine model of asthma. *J Invest Med* 45(7):298A, 1997.
	C51	Klinman DM et al., Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines, *The Journal of Immunology*, 158:3635-3639, 1997.
	C52	Klinman DM et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. *Proc Natl Acad Sci USA* 93(7):2879-83, 1996.
	C53	Krieg AM, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. *J Lab Clin Med* 128(2):128-33, 1996.
	C54	Krieg AM et al., Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. *Antisense Res Dev* 1(2):161-71, Summer 1991.
	C55	Krieg AM et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. *Antisense Nucleic Acid Drug Dev* 6(2):133-9, Summer 1996.
	C56	Krieg AM et al., "Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy", *Proc. Natl. Acad. Sci.*, (1993), 90:1048-1052
	C57	Krieg AM et al., "CpG DNA: A Pathogenic Factor in Systemic Lupus Erythematosus?", *Journal of Clinical Immunology*, (1995) 15:6:284-292
	C58	Krieg AM et al, "Phosphorothioate Oligodeoxynucleotides: Antisense or Anti-Protein?, *Antisense Research and Development*, (1995), 5:241
	C59	Krieg AM et al., "Leukocyte Stimulation by Oligodeoxynucleotides", *Applied Antisense Oligonucleotide Technology*, (1998), 431-448
	C60	Krieg AM et al., CpG motifs in bacterial DNA trigger direct B-cell activation. *Nature* 374:546-9, 1995.
	C61	Krieg AM et al, "The role of CpG dinuleotides in DNA vaccines", Trends in Microbiology, Vol. 6, pp. 23-27, Jan 1998.
	C62	Krieg AM el al, "A Role for Endogenous Retroviral Sequences in the Regulation of Lymphocyte Activation, the Journal of Immunology, Vol. 143, 2448-2451.
	C63	Krieg AM et al., Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs, *Proc. Natl. Acad. Sci. USA*, Vol. 95, pp. 12631-12636, October 1998.
	C64	Kuramoto et al., Oligonucleotide Sequences Required for Natural Killer Cell Activation, *Jpn. J. Cancer Res.*, 83:1128-1131, November 1992.
	C65	Larsen DL et al., Coadministration of DNA Encoding Interleukin-6 and Hemagglutinin Confers Protection from Influenza Virus Challenge in Mice, *Journal of Virology*, Vol. 72, No. 2, pp. 1704-1708, Feb. 1998.
	C66	Lee SW et al., Optimal Induction of Hepatitis C Virus Envelope-Specific Immunity by Bicistronic Plasmid DNA Inoculation with the Granulocyte-Macrophage Colony-Stimulating Factor Gene, *Journal of Virology*, Vol. 72, No. 10, pp. 8430-8436, Oct. 1998.
	C67	Leonard et al., Conformation of Guanine 8-Oxoadenine Base Pairs in the Crystal Structure of d(CGCGAATT(08A)GCG). *Biochemistry*, 31(36):8415-8420, 1992.
	C68	Lipford GB et al., Bacterial DNA as immune cell activator, *Trends Microbiol*, 6(12): 496-500, Dec. 1998.
	C69	Lowell et al., Proteosomes, Emulsomes, and Cholera Toxin B Improve Nasal Immunogenicity of Human Immunodeficiency Virus gp160 in Mice: Induction of Serum, Intestinal, Vaginal, and Lung IgA and IgG, *The Journal of Infectious Diseases*, 175:292-301, 1997.
	C70	Lu Y et al., Macrophage inflammatory protein-1α (MIP-1α) expression plasmid enhances DNA vaccine-induced immune response against HIV-1, *Clin Exp Immunol* 115:335-341, 1999.
	C71	Macfarlane DE and Manzel L, Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. *J Immunol* 160(3):1122-31, Feb 1 1998.

Date 2/9/04

FORM PTO-1449 (Modified)	ATTY. DOCKET NO.	SERIAL NO.
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	C1040/7006	09/316,199
	APPLICANT McCluskie et al.	
	FILING DATE May 21, 1999	GROUP

	C72	Mallon et al., Comparison of antibody response by use of synthetic adjuvant system and Freund complete adjuvant in rabbits, *Am J Vet Res*, Vol. 52, No. 9, pp. 1503-1506, September 1991.
	C74	Mannino RJ et al., Lipid Matrix-Based Vaccines for Mucosal and Systemic Immunization, pp. 363-387.
	C75	Mastrangelo et al. *Seminars in Oncology*. Vol. 23, 1:4-21, 1996.
	C76	Matson S and Krieg AM, Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides. *Antisense Res Dev* 2(4):325-30, Winter 1992.
	C77	McIntyre KW et al., A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation. *Antisense Res Dev* 3(4):309-22, Winter 1993.
	C78	Messina et al., The Influence of DNA Structure on the *in vitro* Stimulation of Murine Lymphocytes by Natural and Synthetic Polynucleotide Antigens. *Cellular Immunology*, 147:148-157, 1993.
	C79	Messina et al., Stimulation of *in vitro* Murine Lymphocyte Proliferation by Bacterial DNA. *J. Immunol.*, Vol. 147, 6:1759-1764, September 15, 1991.
	C80	Mojcik, C., et al., "Administration of a Phosphorothioate Oligonucleotide Antisense Murine Endogenous Retroviral MCF env Causes Immune Effect in vivo in a Sequence-Specific Manner", *Clinical Immunology and Immunopathology*, (1993), 67:2:130-136
	C81	Moldoveanu Z et al., CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus, *Vaccine*, Vol. 16, No. 11/12, pp. 1216-1224, 1998.
	C82	Mottram et al., A novel CDC2-related protein kinase from leishmania mexicana LmmCRK1 is post-translationally regulated during the life cycle. *J. Biol. Chem.* 268:28, 21044-21052 (October 1993).
	C83	Neuzil KM et al., Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine, *Vaccine*, Vol. 15, No. 5, pp. 252-532, 1997.
	C84	*New England BIOLABS 1988-1989 Catalog*
	C85	Nyce JW and Metzger WJ, DNA antisense therapy for asthma in an animal model. *Nature* 385:721-725, 20 Feb 1997.
	C86	Okada E et al., Intranasal Immunization of a DNA Vaccine with IL-12- and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Expressing Plasmids in Liposomes Induces Strong Mucosal and Cell-Mediated Immune Responses Against HIV-1 Antigens, *The Journal of Immunology*, 159:3638-3647, 1997.
	C87	Pisetsky et alo., Stimulation of Murine Lymphocyte Proliferation...Simplex Virus., Life Science, 54:101-107, (1994)
	C88	Pisetsky, D., "Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides", *Molecular Biology Repairs*, (1993) 18:217-221
	C89	Pisetsky, The Immunological Properties of DNA, *The Journal of Immunology*, pp. 421-423 (1996).
	C90	Pisetsky, Immunological Consequences of Nucleic Acid Therapy, *Antisense Research and Development*, 5:219-225 (1995).
	C91	Raz E et al., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. *Proc Natl Acad Sci USA* 93(10):5141-5, 14 May 1996.
	C92	Ribi E et al., Preparation and Antitumor Activity of Nontoxic Lipid A, *Cancer Immunol Immunother*, 12:91-96, 1982.
	C93	Roman M et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. *Nat Med* 3(8):849-54, Aug 1997.
	C94	Sato et al., Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization, *Science*, Vol. 273, pp. 352-354, 1996.
	C95	Schnell et al., Identification and characterization of a Saccharomyces cerevisiae gene (PAR1) conferring resistance to iron chelators. *Eur. J. Biochem.*, 200:487-493.
	C96	Schultz N et al., Effect of DETOX as an adjuvant for melanoma vaccine, *Vaccine*, Vol. 13, No. 5, pp. 503-508, 1995.

Dan 2/9/04

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. C1040/7006	SERIAL NO. 09/316,199
	APPLICANT McCluskie et al.	
	FILING DATE May 21, 1999	GROUP

DA	C97	Schwartz DA et al., Endotoxin responsiveness and grain dust-induced inflammation in the lower respiratory tract. *Am J Physiol* 267(5 Pt 1):L609-17, 1994.
	C98	Schwartz DA et al., The role of endotoxin in grain dust-induced lung disease. *Am J Respir Crit Care Med* 152(2):603-8, 1995.
	C99	Schwartz DA et al., CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. *J Clin Invest* 100(1):68-73, 1 Jul 1997.
	C100	Shirakawa T et al., The inverse association between tuberculin responses and atopic disorder. *Science* 275(5296):77-9, 3 Jan 1997.
	C101	Sin J et al., IL-12 Gene as a DNA Vaccine Adjuvant in a Herpes Mouse Model: IL-12 Enhances Th1-Type CD4+ Cell-Mediated Protective Immunity Against Herpes Simplex Virus-2 Challenge, *The Journal of Immunology*, 162:2912-2921, 1999.
	C102	Sin J et al., In Vivo Modulation of Vaccine-Induced Immune Responses toward a Th-1 Phenotype Increases Potency and Vaccine Effectiveness in a Herpes Simplex Virus Type 2 Mouse Model, *Journal of Virology*, Vol. 73, No. 1, pp. 501-509, Jan. 1999.
	C103	Sparwasser T et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. *Eur J Immunol* 27(7):1671-9, Jul 1997.
	C104	Stein CA et al., Oligonucleotides as inhibitors of gene expression: a review. *Cancer Research*, 48:2659-2668, 1988.
	C105	Stull et al., Antigene, Ribozyme, and Aptamer Nucleic Acid Drugs: Progress and Prospects, *Pharmaceutical Res.*, Vol. 12, 4:465-483, 1995.
	C106	Subramanian et al., Theoretical Considerations on the "Spine of Hydration" in the Minor Groove of d(CGCGAATTCGCG) d(GCGCTTAAGCGC): Monte Carlo Computer Simulation. *Proc. Nat'l. Acad. Sci. USA*, 85:1836-1840, 1988.
	C107	Sun S et al., Mitogenicity of DNA from Different Organisms for Murine B Cells, *The Journal of Immunology*, pp. 3119-3125.
	C108	Tanaka T et al., An antisense Oligonucleotide complementary to a sequence in IG2b increases G2b germline transcripts stimulates B cell DNA synthesis and inhibits immunoglobulin secretion. *J. Exp. Med.*, 175:597-607, 1992.
	C109	Tang D et al., Genetic immunization is a simple method for eliciting an immune response, *Nature*, Vol. 356, pp. 152-154, 12 March 1992.
	C110	Thoelen et al., Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system, *Vaccine*, Vol. 16, No. 17, pp. 708-714, 1998.
	C111	Thorne PS., Experimental grain dust atmospheres generated by wet and dry aerosolization techniques. *Am J Ind Med* 25(1):109-12, 1994.
	C112	Tokunaga T et al., Synthetic Oligonucleotides with Particular Base Sequences form the cDNA Encoding Proteins of *Myobacterium bovis* BCG Induce Interferons and Activate Natural Killer Cells, *Microbiol. Immunol.*, Vol. 36, 1:55-66, 1992.
	C113	Tokunaga et al., A Synthetic Single-Stranded DNA, Ply (dG, dC), Induces Interferon α/β and -γ, Augments Natural Killer Activity and Suppresses Tumor Growth. *Jpn. J. Cancer Res.*, 79:682-686, June 1988.
	C114	Tomasi M et al., Strong mucosal adjuvanticity of cholera toxin within lipid particles of a new multiple emulsion delivery system for oral immunization, *Eur. J. Immunol.*, 27:2720-2725, 1997.
	C115	Tsuji T et al., Enhancement of Cell-Mediated Immunity Against HIV-1 Induced by Coinoculation of Plasmid-Encoded HIV-1 Antigen with Plasmid Expressing IL-12, *Journal of Immunology*, 158:4008-4013, 1997.
	C116	Uhlmann et al., Antisense Oligonucleotides: A New Therapeutic Principle. *Chemical Reviews*, 90:543-584, 1990.
V	C117	Usinger, A comparison of antibody responses to veterinary vaccine antigens potentiated by different adjuvants, *Vaccine*, Vol. 15, No. 17/19, pp. 1902-1907, 1997.

Dlw 2/9/04

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. C1040/7006	SERIAL NO. 09/316,199
	APPLICANT McCluskie et al.	
	FILING DATE May 21, 1999	GROUP

	C118	Vosika G et al., Phase I Study of Intravenous Mycobacterial Cell Wall Skeleton and Trehalose Cimycolate Attached To Oil Droplets, *Journal of Biological Response Modifiers*, 3:620-626, 1984.
	C119	Vosika G et al., Phase I-II Study of Intralesional Immunotherapy with Oil-Attached *Mycobacterium smegmatis* Cell Wall Skeleton and Trehalose Dimycolate, *Cancer Immunol Immunother*, 6, 135-142 (1979).
	C120	Wagner RW, Gene inhibition using antisense oligodeoxynucleotides. *Nature*, 372:L333-335, 1994.
	C121	Wallace et al., Oligonucleotide probes for the screening of recombinant DNA libraries. *Methods in Enzymology*, 152:432-442 (1987).
	C122	Weeratna R et al., Reduction of Antigen Expression from DNA Vaccines by Coadministered Oligodeoxynucleotides, *Antisense & Nucleic Drug Development*, 8:351-356, 1998.
	C123	Weiss R., Upping the Antisense Ante: Scientists bet on profits from reverse genetics. *Science*, 139:108-109, 1991.
	C124	Weiss R., A Plasmid Encoding Murine Granulocyte-Macrophage Colony-Stimulating Factor Increases Protection Conferred by a Malaria DNA Vaccine, *The Journal of Immunology*, Vol. 161, pp. 2325-2332, 1998.
	C125	Whalen R, DNA Vaccines for Emerging Infection Diseases: What If?, *Emerging Infectious Disease*, Vol. 2, 3:168-175, 1996.
	C126	Wu GY et al., Receptor-mediated gene delivery and expression in vivo. *J. Biol. Chem.*, 263:14621-14624, 1988.
	C127	Wu-Pong S., Oligonucleotides: Opportunities for Drug Therapy and Research. *Pharmaceutical Technology*, 18:102-114, 1994.
	C128	Xin KQ et al., Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1, *Immunology*, 94:438-444, 1998.
	C129	Yamamoto S et al., DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. *Microbiol Immunol* 36(9):983-97, 1992.
	C130	Yamamoto S et al., *In vitro* augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from *Mycobacterium bovis* BCG. *Jpn J Cancer Res* 79:866-73, Jul 1988.
	C131	Yamamoto S., Mode of Action of Oligonucleotide Fraction Extracted from Mycobacterium bovis BCG, *Kekkaku*, Vol. 69, 9:29-32, 1994.
	C132	Yamamoto S et al., Unique Palindromic Sequences in Synthetic Oligonucleotides are Required to Induce INF and Augment INF-Mediated Natural Killer Activity. *J. Immunol.*, Vol. 148, 12:4072-4076, June 15, 1992.
	C133	Yamamoto T et al., Ability of Oligonucleotides with Certain Palindromes to Induce Interferon Production and Augment Natural Killer Cell Activity is Associated with Their Base Length. *Antisense Res. and Devel.*, 4:119-123, 1994.
	C134	Yamamoto et al., Lipofection of Synthetic Oligodeoxyribonucleotide Having a Palindromic Sequence AACGTT to Murine Splenocytes Enhances Interferon Production and Natural Killer Activity. *Microbiol. Immunol.*, Vol. 38, 10:831-836, 1994.
	C135	Yamamoto T et al., Synthetic Oligonucleotides with Certain Palindromes Stimulate Interferon Production of Human Peripheral Blood Lymphocytes *in vitro*. *Jpn. J. Cancer Res.*, 85:775-779, 1994.
	C136	Yi, Ae-Kyung et al., IFN-γ Promotes IL-6 and IgM Secretion in Response to CpG Motifs in Bacterial DNA and Oligonucleotides, *The Journal of Immunology*, pp. 558-564 (1996).
	C137	Yi, Ae-Kyung et al., Rapid Immune Activation by CpG Motifs in Bacterial DNA, *The Journal of Immunology*, pp. 5394-5402 (1996).
	C138	Zhao Q et al., Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. *Blood* 84(11):3660-6, 1 Dec 1994.
	C139	Zhao Q et al., Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. *Antisense Res Dev* 3(1):53-66, Spring 1993.

2/19/04

EXAMINER	DATE CONSIDERED 2/9/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.